Clinical trial · Observational
Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia (CML) in All Lines of Treatment
Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia (CML) in All Lines of Therapy: An Analysis of Medicare Fee-for-Service (FFS) Data
NCT07188428CI-TRIAL-00095643completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study was to evaluate the real-world treatment patterns, healthcare resource use and costs among patients newly diagnosed with CML who were treated with tyrosine kinase inhibitors (TKIs) in first- and second-line therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia, Chronic Myeloid | Chronic Myeloid Leukemia, BCR-ABL1 Positive | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- 1L Cohort
- description
- Adult patients newly diagnosed with CML who received 1L treatment with imatinib, dasatinib, nilotinib, or bosutinib.
- label
- 2L Cohort
- description
- Adult patients from the 1L Cohort with a subsequent line of treatment (i.e., second treatment) with imatinib, dasatinib, nilotinib, bosutinib, ponatinib, or asciminib.
Primary outcomes (3)
- measure
- Number of Patients Who Switched to Another CML-related Treatment by TKI Generation and Treatment Profile
- timeFrame
- Up to approximately 6 years
- measure
- Number of Patients Who Switched to Another CML-related Treatment Within 6 Months of Starting Treatment by TKI Generation and Treatment Profile
- timeFrame
- 6 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria: 1. L Cohort: * Patients had at least one diagnosis for CML (International Classification of Diseases, 10th Revision, Clinical Modification \[ICD-10-CM\]: C92.1x) during the observation period. * Patients ≥18 years of age as of the first CML diagnosis. * Patients received imatinib, dasatinib, nilotinib, or bosutinib in 1L. * Patients initiated 1L within a maximum of 3 months following the first observed CML diagnosis. * Patients had at least 12 months of continuous enrollment prior to the index date. * Patients had at least 6 months of continuous enrollment post index date (including index date). 2. L Cohort: * Patients in the 1L cohort. * Patients received imatinib, dasatinib, nilotinib, bosutinib, ponatinib or asciminib in 2L. * Patients with at least 12 months of continuous enrollment prior to the index date. * Patients with at least 6 months of continuous enrollment post index date (including index date). Exclusion criteria: 1. L Cohort: * Patients with medical services with a procedure code for imatinib any time during the observation period. * Patients with a diagnosis for CML remission (identified by ICD-10-CM code: C92.11) or CML relapse (ICD-10-CM code: C92.12) any time in the baseline period before the 1L initiation. * Patients with a medical claim associated with a clinical trial drug during the baseline period before the 1L initiation up to the end of the observation period. * Patients who received chemotherapy, or a TKI of interest or had a hematopoietic stem cell transplantation (HSCT) during the baseline period before 1L initiation. 2. L Cohort: * Patients with a diagnosis for CML remission (identified by ICD-10-CM code: C92.11) or CML relapse (ICD-10-CM code: C92.12) any time before the 2L initiation.
References
Publications (0)
Data not yet available
No reference posted for this study.